Ronald S. Braithwaite, MD

Professor, Department of Population Health

Professor, Department of Medicine

Summary

OMB No. 0925-0001 and 0925-0002 (Rev. 09/17 Approved Through 03/31/2020)

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person.  DO NOT EXCEED FIVE PAGES.

NAME: Braithwaite, R. Scott

eRA COMMONS USER NAME (credential, e.g., agency login): RSBRAITHWAITE

POSITION TITLE: Tenured Professor of Population Health and Medicine

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

INSTITUTION AND LOCATION

DEGREE

(if applicable)

 

Completion Date

MM/YYYY

 

FIELD OF STUDY

 

Massachusetts Institute of Technology, Cambridge, MA

BS

08/1988

Physics

SUNY at Stony Brook School of Medicine Stony Brook, NY

MD

05/1993

Medicine

University of Washington School of Medicine Seattle, WA

Residency

06/1996

Medicine

Tufts School of Medicine, Boston, MA

Fellow

06/2001

Decision Analysis

University of PIttsburgh School of Medicine

MSc

06/2004

Clinical Research

American College of Physicians

Fellow

12/2008

 

A.Personal Statement

 

I am Professor of Medicine and Population Health, trained in general internal medicine and decision analysis. My background is in decision analytic modeling, evidence synthesis, comparative effectiveness research, and cost-effectiveness analysis. In addition, I am a practicing physician who is fellowship-trained in decision analysis. I am the Chief, Division of Comparative Effectiveness and Decision Sciences, in the Department of Population Health at NYU School of Medicine, which was created to facilitate research projects at the interface of clinical research and the decision sciences. In 2013, I was the President of the Society for Medical Decision Making (SMDM), the leading academic organization to improve decisions in health care. I have extensive experience developing, calibrating, validating, and informing public policy with mathematical models in multiple clinical domains. I have been PI or Co-PI on several NIH and AHRQ funded projects and have collaborated with the WHO and local and national health departments. I have mentored over 30 pre- and post-doctoral trainees and over 15 junior faculty members, most of whom have gone on to research careers and successfully competed for funding.

 

B.        Positions and Honors

Positions and Employment:

1984-87           Undergraduate Research Opportunities Program, Massachusetts Institute of Technology;                                                                        Cambridge, MA

1988-89           Research Assistant, Johns Hopkins University; Baltimore, MA

1990                Summer Research Student, Woods Hole Oceanographic Institute; Woods Hole, MA

1991                Chair, Pepper Commission Study Group, American Medical Student Association

1991-92           Associate Trustee, American Medical Student Association

1993-94           Intern, Internal Medicine, University of Washington

1994-96           Resident, Internal Medicine, University of Washington

1996-97           Hospitalist, Grays Harbor Community Hospital; Aberdeen, WA

1996-99           Acute Care Physician, VAMC Roseburg, OR

1999-01           Research Fellow, Clinical Decision Making, Tufts University/New England Medical Center

1999-01           Acute and Primary Care Physician: Dorchester House Community Health Center, Boston, MA

2001-04           Core Faculty Member, Center for Research on Health Care, University of Pittsburgh

2001-04     Assistant Professor of Medicine, Division of General Internal Medicine, Sections of Decision Sciences and Hospital Medicine, University of Pittsburgh

2004-07           Assistant Professor of Medicine, Section of General Internal Medicine, Yale University

2007-09           Associate Professor of Medicine, Section of General Internal Medicine, Yale University

2009-               Associate Professor of Medicine, Division of General Internal Medicine, New York University SoM

2009                Chief, Section of Value and Comparative Effectiveness, NYU School of Medicine

2012                Associate Professor of Medicine and Chief, Division of Comparative Effectiveness and Decision Science, 

New York University School of Medicine

2013-               Tenured Professor of Medicine and Chief, Division of Comparative Effectiveness and Decision                                                   Science, New York University School of Medicine

Honors:

1993          MD with Distinction in Research Award, State University of NY at Stony Brook

2000                Lee B. Lusted Prize, best abstract, Society for Medical Decision Making

2002          Finalist, Hamolsky Award, Society for General Internal Medicine

2002          Best Short Course, 24th Annual Meeting, Society for Medical Decision Making

2003          Finalist, Hamolsky Award, Society for General Internal Medicine

2006          Cited for exceptional quality of peer reviews, Annals of Internal Medicine

2006          Yale nominee for Robert Wood Johnson Physician Faculty Scholars award

2007          Cited for exceptional quality of peer reviews, Annals of Internal Medicine

2007-10     Robert Wood Johnson Physician Faculty Scholar

2012          Awarded Distinguished Alumni Award University of Pittsburgh Training Program

2013          Elected President of Society of Medical Decision Making (SMDM)

C.        Contribution to Science
  1. Evaluating alternative monitoring strategies for HIV infected persons in Sub-Saharan Africa. Our team has developed a validated HIV computer simulation model which we have used to compare alternative monitoring strategies for HIV infected individuals who have started on ART. Our work is distinct in that it systematically compared an exhaustive set of plausible monitoring possibilities, including many that were feasible yet not under active programmatic consideration, and it linked impact on HIV progression with impact on HIV transmission. In addition, it compared the value against simultaneously resource constrained interventions that were programmatic priorities, rather than against arbitrary thresholds (as is the more common practice). 

    1. Braithwaite RS, Nucifora KA, Toohey C, et al. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa? AIDS. 2014;28 Suppl 1:S73-83. PMID: 24468949

    2. Keebler D, Revill P, Braithwaite S, et al. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Lancet Global Health. 2014; 2(1):e35-43. PMID: 25104633

    3. Khademi A, Braithwaite RS, Saure D, Schaefer AJ, Nucifora K, Roberts MS. Should expectations about the rate of new antiretroviral drug development impact the timing of HIV treatment initiation and expectations about treatment benefits? PLoS One. 2014;9(6):e98354. PMID: 24963883

    4. Kessler J, Nucifora K, Li L, Uhler L, Scott Braithwaite RS. Impact and cost effectiveness of hypothetical strategies to enhance retention-in-care within HIV treatment programs in East Africa. Value Health. 2015 Dec;18(8):946-55. PMID: 26686778

 

  1. Calibrated and validated simulation of HIV disease to estimate the impact of alcohol on survival. Previous research has shown that alcohol consumption is associated with decreased antiretroviral adherence, and decreased adherence results in poorer outcomes. However the magnitude of alcohol’s impact on survival is unknown. Using clinical data we incorporated data into our HIV simulation model.

    1. Braithwaite RS, Nucifora KA, Kessler J, et al. Impact of Interventions Targeting Unhealthy Alcohol Use in Kenya on HIV Transmission and AIDS-Related Deaths. Alcohol Clin Exp Res. 2014;38(4):1059-1067. PMID: 24428236

    2. Braithwaite RS, Nucifora KA, Kessler J, et al. How inexpensive does an alcohol intervention in Kenya need to be in order to deliver favorable value by reducing HIV-related morbidity and mortality? J. Acquir. Immune Defic. Syndr. 2014;66(2):e54-58. PMID: 24828269

    3. Braithwaite RS, Bryant K. Influence of Alcohol Consumption on Adherence to and Toxicity of Antiretroviral Therapy and Survival. Alcohol Research & Health. 2010;33(3):280-287. PMCID: PMC3860503

       

  2. Optimize quality and value in healthcare. Given the importance of working within limited resources, my research has focused on optimizing quality and value in healthcare in Sub-Saharan Africa and other developing countries through the use of mathematical modeling. This body of work includes research evaluating the cost, effectiveness, and value of different strategies for antiretroviral monitoring, eligibility guidelines for antiretroviral therapy, enhancing retention-in-care, and interventions targeting unhealthy drug use. This research is currently being used to inform the next generation of WHO guidelines.

     

    1. Braithwaite RS, Nucifora KA, Toohey C, Kessler J, Uhler LM, Mentor SM, Keebler D, Hallett T. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa? AIDS. 2014 Jan; 28 Suppl 1:S73-83. doi: 10.1097/QAD.0000000000000110. PubMed PMID: 24468949.

    2. Keebler D, Revill P, Braithwaite S, et al. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Lancet Global Health. 2014;2(1): e35-43. PMID: 25104633

    3. Kessler J, Braithwaite RS. Modeling the cost-effectiveness of HIV treatment: how to buy the most 'health' when resources are limited. Current opinion in HIV and AIDS. 2013; 8(6):544-549. PMID: 24100874

 

  1. Making evidence assumptions transparent and development of objective decision rules. My early work focused on the development of objective rules for decision making based on model results, and helping decision makers know when to “trust the model” because of concerns about biased inputs. In decision making, providing objective rules helps guide providers and payers to know when it is most efficient and effective to adapt clinical guidelines. This research has the potential to both improve healthcare quality and to reduce unnecessary resource expenditures, as well as to increase the use of modeling in the policy arena.

    1. R. Scott Braithwaite, David O. Meltzer, Joseph T. King, Jr., Douglas Leslie and Mark S. Roberts. What Does the Value of Modern Medicine Say about the $50,000 per Quality-Adjusted Life-Year Decision Rule? Medical Care . 2008 Apr; Vol. 46, No. 4, pp. 349-356 PMID: 18362813

    2. Braithwaite RS, Roberts MS, Justice AC. Incorporating quality of evidence into decision analytic modeling. Ann Intern Med. 2007;146(2):133-141. PMID: 17227937

 

Complete List of Published Work in MyBibliography

http://www.ncbi.nlm.nih.gov/sites/myncbi/ronald.braithwaite.2/bibliography/47552355/public/?sort=date&direction=ascending

 

D.        Research Support

Ongoing Research Support

1U01AA020799 (Braithwaite) NIH/NIAID                                                                                                                                                      09/06/11-08/31/21       Consortium to Improve Outcomes in HIV/AIDS, Alcohol, Aging & Multi-substance use (COMpAAAS)

Our proposal creates an interactive, web-based simulation model of HIV transmission that can help decision makers prioritize which intervention designs are most effect by tailoring results to patients and feasibility constraints. Role: Principal Investigator

 

5R01AA024706-02 (Braithwaite) NIH/NIAAA                                                                                                                        09/15/16 – 06/30/21

Should screening and treatment strategies for unhealthy alcohol misuse in HIV infected persons vary with smoking, depression, and substance abuse?

 We propose systematically addressing related questions by combining analysis of temporal data with mathematical models of HIV progression, transmission, and other sources of morbidity and mortality. With our aims we will identify whether diagnosis of a patient with current alcohol misuse and/or ≥1 syndemic conditions should trigger screening for each of the other syndemic conditions (Aim 1a), how often a patient with prior alcohol misuse and/or ≥1 syndemic conditions should be monitored for each of the syndemic conditions, and what are the most beneficial treatment strategies for a patient with alcohol misuse and ≥1 syndemic conditions (Aim 2).

 

1R01 DA040480-01A1(Gwadz/Collins, MPI) NIDA                                                                                                               04/01/16-03/31/21

Using MOST to Optimize an HIV Care Continuum Intervention for Vulnerable Populations

The aims of the present study are: Aim 1: Using a highly efficient experimental design, identify which of five components contribute meaningfully to improvement in the primary outcome, viral suppression, and secondary outcomes, absolute viral load, ART adherence, and engagement in HIV primary care, all assessed via objective biomarkers or through the medical record. Aim 2: Identify mediators and moderators of the efficacy of each intervention component (e.g., substance use history, sexual minority status), and also of interaction effects between components. Aim 3: Using a mathematical modeling approach, build the most cost-effective and efficient intervention package from the components found to be efficacious in Aim 1. Role: Co-Investigator

 

1P30HS24376 (Horwitz) AHRQ                                                                                                                                                                                 09/30/15-09/30/19      

 NYU Patient Imaging Quality and Safety Laboratory (PIQS Lab)

The NYU Patient Imaging Quality and Safety Laboratory (PIQS Lab) will be a multidisciplinary laboratory that joins clinicians and operations, management, design and human factors experts to improve the safety and quality of radiologic imaging and procedures for outpatients and inpatients. Comprehensive redesign using a design/engineering approach can transform the patient experience and radically improve safety.

Role: Co-Investigator

 

1U01AA021990 (Schensul, Saggurti & Schensul) NIH/NIAAA                                                                                 02/15/14-01/31/19      

Alcohol and ART Adherence: Assessment, Intervention and Modeling in India

This study seeks to provide an understanding of current ART implementation and alcohol and other challenges to ART adherence; identify and test multilevel interventions that can reduce alcohol consumption as a central factor in enhancing adherence; and develop predictive models for use in India and elsewhere that provides a basis for allocating intervention resources in the most cost-effective way to maximize adherence, reduce years and quality of life lost to HIV, and minimize HIV transmission. Role: Co-Investigator

 

1R25EB020389-01A1 (Braithwaite and Recht) NIH                                                                                                              12/01/15-11/30/18

Discovering the Value of Imaging: A Collaborative Training Program in Biomedical Big Data and Comparative Effectiveness Research for the Field of Radiology

This proposal addresses this lack of evidence-based use of imaging by developing a collaborative training program in comparative effectiveness research (CER) and biomedical big data that will be accessible to a large number of imagers and imaging trainees. Role: Co- Investigator

 

1R01MH101028-A1 (Nash & Irvine) NIH/NIMH                                                                                                                               09/26/13-08/31/18      

HIV care coordination: comparative effectiveness, outcome determinants and costs

The goal of the study is to 1) assess the effectiveness of the intervention by comparing primary outcomes among participants with those of similar PLWH in HIV care who do not receive the intervention; 2) among those who enroll in the intervention, identify individual and program-level determinants of care engagement and VL suppression up to 36 months following enrollment; and 3) assess the cost-effectiveness  of the relative to usual care outside the, considering downstream cost-savings and individual and public health benefits due to improved VL suppression and HIV infections averted. Role: Co-Investigator

 

1R01AA020836 (Lee) NIH/NIAAA                                                                                                                                                                 08/01/13-04/30/18      

Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care

This study seeks to estimate the effectiveness of newly FDA-approved extended-release naltrexone (XR-NTX) when initiated by opioid users leaving a larger urban jail. Role: Co-Investigator

 

 

1R01CA173754 (Crothers) NIH/PEPFAR                                                                                                                                         04/10/13-03/31/18      

Benefits and Harms of Lung Cancer Screening in HIV Infection

This project proposes to develop a mathematical model that estimates the potential benefits of screening, identifies the appropriate candidates for screening, and determines the best screening regimen for HIV+ individuals. Role: Co-Investigator

 

 

1R25EB020389-01A1 (Braithwaite and Recht) NIH                                                                                                              12/01/15-11/30/18      

Discovering the Value of Imaging: A Collaborative Training Program in Biomedical Big Data and Comparative Effectiveness Research for the Field of Radiology

This proposal addresses this lack of evidence-based use of imaging by developing a collaborative training program in comparative effectiveness research (CER) and biomedical big data that will be accessible to a large number of imagers and imaging trainees. Role: Co-Principal Investigator

 

1U24AA022007 (Braithwaite) NIH/NIAAA                                                                                                                                         09/15/12-08/31/18

The Operations Research Collaboration for Alcohol Abuse and AIDS: ORCAAA

The goal of the study is to develop an Implementation Science Resource Core to support the research efforts of several CHARRT consortia, building upon existing infrastructure within these consortia. Role: PI

 

Completed Research Support

1R01DA034637 (Hagan) NIH                                                                                                                                                                                                07/01/13-04/30/17      

Addressing hepatitis C and hepatocellular carcinoma: The current and future epidemics

The goal of this project is to use simulations to determine the combination of effective interventions for particular budget and epidemiologic scenarios that a) minimize HCV transmission, b) eradicate persistent HCV infections, c) prevent the most HCC, and d) maximize life expectancy and quality-adjusted life expectancy. Role: Co-Investigator

 

R01AI100059 El-Sadr (PI) NIH/PEPFAR                                                                              06/15/12-05/31/16(NCE)                                                             

A combination intervention strategy for linkage and retention: Swaziland

This project is focused on the issue of linkage of HIV positive patients to care and their retention in care.

Role: Co-Investigator

 

1R01AI099970 Braithwaite(PI) NIH/NIAID                                                                                                                                        05/15/12-04/30/16(NCE) 

Implementation Science to optimize HIV prevention in East Africa PEPFAR programs

The goal of this project is to identify more efficient ways to increase the amount of health benefits from PEPFAR resources with a specific emphasis on retention-in-care. Role: Principal Investigator

 

1R01DA032080 (Kurth) NIH/NIDA                                                                                                                                                                                                                07/15/11-04/30/16      

Test and Linkage to Care (TLC_IDU Kenya)

The goal of this study is to reduce HIV transmission due to injecting drug use (IDU) in Kenya. This goal will be accomplished by leveraging a first-ever needle and syringe exchange program (NSP) platform that the Government of Kenya (GoK) will launch. Role: Co-Investigator

 

R01DA032083 (Gwadz) NIH/NIDA                                                                                        07/15/11-04/30/16

Peer Driven Intervention to Seek, Test, & Treat Heterosexuals at High Risk for HIV

This five-year study aims to evaluate the efficacy of a brief, scalable, peer driven intervention to seek and test heterosexuals at high risk for HIV, and link them to care with high retention if found HIV infected. It will also examine the cost effectiveness of the intervention and compare the efficiency and costs of two sampling methods for the population: respondent driven sampling and venue based sampling. Role: Co-Investigator

 

Phone

212-263-4964

Academic office

227 East 30th Street

Sixth Floor

New York, NY 10016

Is this your profile?

Professor, Department of Population Health

Professor, Department of Medicine

Dir Division of Comparative Effec & Decision Sci

MD from State University of New York at Stony Brook

Stevens, Elizabeth R; Nucifora, Kimberly; Zhou, Qinlian; Braithwaite, R Scott; Cleland, Charles M; Ritchie, Amanda S; Kutnick, Alexandra H; Gwadz, Marya V

Journal of acquired immune deficiency syndromes. JAIDS. 2018 Feb 1; 77(2):183-192

Kang, Stella K; Scherer, Laura D; Megibow, Alec J; Higuita, Leslie J; Kim, Nathanael; Braithwaite, R Scott; Fagerlin, Angela

American journal of roentgenology (1976). 2017 Nov 15; 1-7

Hajizadeh, Negin; Stevens, Elizabeth R; Applegate, Melanie; Huang, Keng-Yen; Kamboukos, Dimitra; Braithwaite, R Scott; Brotman, Laurie M

BMC public health. 2017 Oct 10; 17(1):796-796

Rebeiro, Peter F; Bakoyannis, Giorgos; Musick, Beverly S; Braithwaite, Ronald S; Wools-Kaloustian, Kara K; Nyandiko, Winstone; Some, Fatma; Braitstein, Paula; Yiannoutsos, Constantin T

Journal of acquired immune deficiency syndromes. JAIDS. 2017 Oct 01; 76(2):141-148

Ruggles, Kelly V; Patel, Anik R; Schensul, Stephen; Schensul, Jean; Nucifora, Kimberly; Zhou, Qinlian; Bryant, Kendall; Braithwaite, R Scott

PLoS one. 2017 Sep 5; 12(9):e0184179-e0184179e0184179

Loeb, Stacy; Curnyn, Caitlin; Fagerlin, Angela; Braithwaite, R Scott; Schwartz, Mark D; Lepor, Herbert; Carter, H Ballentine; Ciprut, Shannon; Sedlander, Erica

Patient education & counseling. 2017 Sep 1; ?-?

Cole, Helen; Thompson, Hayley S; White, Marilyn; Browne, Ruth; Trinh-Shevrin, Chau; Braithwaite, Scott; Fiscella, Kevin; Boutin-Foster, Carla; Ravenell, Joseph

American journal of public health. AJPH. 2017 Jul 20; 107(9):1433-1440

Uyei, Jennifer; Li, Lingfeng; Braithwaite, R Scott

BMJ global health. 2017 Jul 20; 2(2):e000195-e000195